Synlab (SYAB.VI) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Market Cap: $3.3BPipeline: 1 drugFounded: 1994Employees: >23,000HQ: Munich, Germany

Overview

Founded in 1994 and headquartered in Munich, SYNLAB has grown through strategic consolidation to become Europe's preeminent diagnostic services platform, generating EUR 2.54 billion in 2025 revenue. The company's mission is to provide actionable diagnostic information for healthy lives and well-being for all, leveraging a network of over 300 laboratories and 1,800 collection points. Its strategy focuses on geographic expansion, operational excellence, and advancing personalized diagnostics to solidify its leadership in a rapidly consolidating global sector.

Diagnostics

Technology Platform

Integrated network of over 300 laboratories and 1,800+ collection points, leveraging scale, automation, AI, and a proprietary IT/digital backbone to deliver efficient, high-volume diagnostic services.

Pipeline

1

1 drug in pipeline

Drug	Indication	Stage	Watch
MGB-BP-3	Healthy	Phase 1

Opportunities

SYNLAB is poised to benefit from the long-term growth drivers of aging populations, increased chronic disease testing, and the shift to personalized medicine.

Key opportunities include further consolidation of fragmented European and emerging markets, expansion of high-value molecular and genetic testing services, and securing more public-private partnership contracts to provide core diagnostic infrastructure.

Risk Factors

Major risks include regulatory and reimbursement pressure from cost-conscious public healthcare systems across its many operating countries, execution risks associated with its acquisition-heavy growth strategy, and operational risks related to maintaining quality and data security across a vast, complex network.

Competitive Landscape

SYNLAB competes globally with large-scale players like Quest Diagnostics, LabCorp, Eurofins, and Sonic Healthcare, and locally with national laboratory chains and hospital labs. Its primary competitive advantages are its pan-European scale, integrated network efficiency, strong physician brand, and financial resources for continued investment and consolidation.

More companies in Germany →